Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 5HIV Infections 4Acquired Immunodeficiency Syndrome 4Sarcoma, Kaposi 3Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tumor Virus Infections 1Triple Negative Breast Neoplasms 1Solid Cancers 1Sarcoma 1Papillomavirus Infections 1Neoplasm Metastasis 1Breast Neoplasms 1Breast Carcinoma In Situ 1Anus Neoplasms 1Advanced Neoplasm 1Adult Solid Neoplasm 1AIDS-Related Complex 1

Interventions

pembrolizumab 26Gemcitabine 20Cisplatin 12Nivolumab 11Carboplatin 8Paclitaxel 7Docetaxel 7atezolizumab 6durvalumab 5Radiotherapy 5fludarabine 4enfortumab vedotin 4Ipilimumab 4Cyclophosphamide 4Vorinostat 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Filgrastim 3Doxorubicin 3zimberelimab 2vocimagene amiretrorepvec 2tremelimumab 2romidepsin 2poly ICLC 2infigratinib 2erdafitinib 2cc-486 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urinary Bladder Neoplasms × Interferon alpha-2 × Clear all
NCT00082719 2015-05-14

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡